Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer

Pancreatic cancer is among the most lethal malignant neoplasms, and few patients with pancreatic cancer benefit from immunotherapy. We retrospectively analyzed advanced pancreatic cancer patients who received PD-1 inhibitor-based combination therapies during 2019–2021 in our institution. The clinica...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Xin, Shi, Zhan, Tong, Fan, Lu, Changchang, Zhu, Yahui, Wang, Qiaoli, Gu, Qing, Qian, Xiaoping, Meng, Fanyan, Liu, Baorui, Du, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Immunotherapy - Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026926/
https://www.ncbi.nlm.nih.gov/pubmed/36809234
http://dx.doi.org/10.1080/21645515.2023.2178791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10026926/
https://www.ncbi.nlm.nih.gov/pubmed/36809234
http://dx.doi.org/10.1080/21645515.2023.2178791

Ejemplares similares